RxDoctor Payments Data

Kevin Bistline

Optometrist · Plymouth Meeting, PANPI 1538311600

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $211,410 of the $301,633 with a category attached, or 70.1%. 9 manufacturers reported payments, led by Bausch & Lomb, A Division Of Bausch Health US, LLC at 50.0% of the total. Reporting peaked in 2019 at $111,756 and has fallen 58.0% since, to $46,981 in 2024. Among optometrist clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$301,633in general payments, 2019–2025

Across 577 payments — averaging $522.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$151K
  • Bausch & Lomb Americas Inc.$149K
  • Johnson & Johnson Vision Care, Inc.$653
  • Alcon$405
  • Coopervision Inc.$266
  • AbbVie$160
  • plus $260 from 3 others

What the payments were for

  • Consulting fees$24,1388%
  • Speaking & faculty fees$211,41070%
  • Travel & lodging$51,08917%
  • Food & beverage$14,9975%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$301,633 in reported general payments places this provider in the 95th percentile of 2,165 optometrist providers in Pennsylvania.

See all optometrist providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$18,815
Medicare patients
101
Services billed
226

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyzultaLatanoprostene Bunod21$8,793
Latanoprost96$675
Tobramycin-DexamethasoneTobramycin/Dexamethasone14$602

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Vyzulta$149,050$8,79321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,165 optometrist providers in Pennsylvania.

Other optometrist in Plymouth Meeting

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →